OAS1 Antikörper (AA 296-395)

Produktnummer ABIN7142170

Produktdetails anti-OAS1 Antikörper

Target: OAS1 (2',5'-Oligoadenylate Synthetase 1, 40/46kDa (OAS1))

Bindungsspezifität: AA 296-395

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser OAS1 Antikörper ist unkonjugiert

Applikation: Immunohistochemistry (IHC), ELISA

Kreuzreaktivität: Human

Aufreinigung: >95%, Protein G purified

Immunogen: Recombinant Human 2\'-5\'-oligoadenylate synthase 1 protein (296-395AA)

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: Recommended dilution: IHC:1:20-1:200,

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Buffer: Preservative: 0.03 % Proclin 300
Constituents: 50 % Glycerol, 0.01M PBS, pH 7.4

Konservierungsmittel: ProClin

Vorsichtsmaßnahmen: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: -20 °C,-80 °C

Informationen zur Lagerung: Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Details zu OAS1

Target: OAS1 (2',5'-Oligoadenylate Synthetase 1, 40/46kDa (OAS1))

Andere Bezeichnung: OAS1 (OAS1 Produkte)

Synonyme: OAS1 antikoerper, IFI-4 antikoerper, OIAS antikoerper, OIASI antikoerper, L3 antikoerper, Pp2a2 antikoerper, 2',5'-oligoadenylate synthetase 1 antikoerper, 2'-5'-oligoadenylate synthetase 1 antikoerper, 2'-5' oligoadenylate synthetase 1A antikoerper, protein phosphatase 2 catalytic subunit beta antikoerper, OAS1 antikoerper, Oas1a antikoerper, Ppp2cb antikoerper, Oas1 antikoerper

Hintergrund:

Background: Interferon-induced, dsRNA-activated antiviral enzyme which plays a critical role in cellular innate antiviral response. In addition, it may also play a role in other cellular processes such as apoptosis, cell growth, differentiation and gene regulation. Synthesizes higher oligomers of 2\'-5\'-oligoadenylates (2-5A) from ATP which then bind to the inactive monomeric form of ribonuclease L (RNase L) leading to its dimerization and subsequent activation. Activation of RNase L leads to degradation of cellular as well as viral RNA, resulting in the inhibition of protein synthesis, thus terminating viral replication. Can mediate the antiviral effect via the classical RNase L-dependent pathway or an alternative antiviral pathway independent of RNase L. The secreted form displays antiviral effect against vesicular stomatitis virus (VSV), herpes simplex virus type 2 (HSV-2), and encephalomyocarditis virus (EMCV) and stimulates the alternative antiviral pathway independent of RNase L.

Aliases: (2 5')oligo(A) synthetase 1 antibody, (2-5'')oligo(A) synthase 1 antibody, 2 5 Oligoadenylate Synthetase 1 antibody, 2 5' oligo A synthase 1 antibody, 2 5' oligo A synthetase 1 antibody, 2 5A synthase 1 antibody, 2 5A synthetase 1 antibody, 2' 5' oligo A synthetase 1 antibody, 2' 5' oligoadenylate synthetase 1 40/46 kDa antibody, 2' 5' oligoadenylate synthetase 1 antibody, 2' 5' oligoisoadenylate synthetase 1 antibody, 2''-5''-oligoadenylate synthase 1 antibody, 2'5' oligo A synthetase 1 antibody, 2'5' oligoadenylate synthetase 1 antibody, 2'5' oligoisoadenylate synthetase 1 antibody, 2-5A synthase 1 antibody, E18/E16 antibody, IFI 4 antibody, IFI4 antibody, OAS 1 antibody, OAS1 antibody, OAS1_HUMAN antibody, OIAS antibody, OIASI antibody, p46/p42 OAS antibody

UniProt: P00973

Pathways: Hepatitis C